Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jose Nativi

Showing results (11-20 of 80) with videos related to

Pageof 8
Sort By:
JHLT Open|March 27, 2025
Impella 5.5 in left ventricular noncompaction syndrome as bridge to heart transplantShriya Sharma, Jose Ruiz, Pankaj Garg, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|February 14, 2025
Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium's treatment affordability patient and caregiver surveySabrina Rebello, Kristen Hsu, Jose Nativi-Nicolau, et al.
European Heart Journal|May 30, 2015
Shortness of breath and cardiac conduction abnormality caused by infiltrative cardiomyopathyPromporn Suksaranjit, John J Ryan, Frederick T Han, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 26, 2019
Cost-effectiveness of technetium pyrophosphate scintigraphy <i>versus</i> heart biopsy for the diagnosis of transthyretin amyloidosisNatalia Ruiz-Negrón, Jose Nativi-Nicolau, Mathew S Maurer, et al.
ESC Heart Failure|August 25, 2021
Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACTJose Nativi-Nicolau, Daniel P Judge, James E Hoffman, et al.
Home Healthcare Now|January 8, 2021
Home Healthcare Nursing Visits for Nonhomebound Patients With Heart Failure After Hospital Discharge: A Quality-Improvement Pilot ProjectYoujeong Kang, Favel L Mondesir, Dawn Young, et al.
Clinical Medicine Insights. Cardiology|June 9, 2021
Best Practices in Specialized Amyloidosis Centers in the United States: A Survey of Cardiologists, Nurses, Patients, and Patient AdvocatesJose Nativi-Nicolau, Nitasha Sarswat, Johana Fajardo, et al.
Future Cardiology|March 17, 2022
How did transthyretin amyloid cardiomyopathy progress in patients who took placebo in the study ATTR-ACT? A plain language summaryJose Nativi-Nicolau, Daniel P Judge, James E Hoffman, et al.
Journal of Comparative Effectiveness Research|June 13, 2024
Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature reviewJose Nativi-Nicolau, Ali Yilmaz, Noel Dasgupta, et al.
Journal of Comparative Effectiveness Research|June 18, 2021
Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathyMark H Rozenbaum, Samuel Large, Rahul Bhambri, et al.
Pageof 8

Showing results (11-20 of 80) with videos related to

Sort By:
Pageof 8
JHLT Open|March 27, 2025
Impella 5.5 in left ventricular noncompaction syndrome as bridge to heart transplantShriya Sharma, Jose Ruiz, Pankaj Garg, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|February 14, 2025
Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium's treatment affordability patient and caregiver surveySabrina Rebello, Kristen Hsu, Jose Nativi-Nicolau, et al.
European Heart Journal|May 30, 2015
Shortness of breath and cardiac conduction abnormality caused by infiltrative cardiomyopathyPromporn Suksaranjit, John J Ryan, Frederick T Han, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 26, 2019
Cost-effectiveness of technetium pyrophosphate scintigraphy <i>versus</i> heart biopsy for the diagnosis of transthyretin amyloidosisNatalia Ruiz-Negrón, Jose Nativi-Nicolau, Mathew S Maurer, et al.
ESC Heart Failure|August 25, 2021
Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACTJose Nativi-Nicolau, Daniel P Judge, James E Hoffman, et al.
Home Healthcare Now|January 8, 2021
Home Healthcare Nursing Visits for Nonhomebound Patients With Heart Failure After Hospital Discharge: A Quality-Improvement Pilot ProjectYoujeong Kang, Favel L Mondesir, Dawn Young, et al.
Clinical Medicine Insights. Cardiology|June 9, 2021
Best Practices in Specialized Amyloidosis Centers in the United States: A Survey of Cardiologists, Nurses, Patients, and Patient AdvocatesJose Nativi-Nicolau, Nitasha Sarswat, Johana Fajardo, et al.
Future Cardiology|March 17, 2022
How did transthyretin amyloid cardiomyopathy progress in patients who took placebo in the study ATTR-ACT? A plain language summaryJose Nativi-Nicolau, Daniel P Judge, James E Hoffman, et al.
Journal of Comparative Effectiveness Research|June 13, 2024
Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature reviewJose Nativi-Nicolau, Ali Yilmaz, Noel Dasgupta, et al.
Journal of Comparative Effectiveness Research|June 18, 2021
Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathyMark H Rozenbaum, Samuel Large, Rahul Bhambri, et al.
Pageof 8